A Phase I Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of OratecanTM in Patients With Advanced Solid Cancer((Q1DX5/W)X2 for 3W).
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2014
At a glance
- Drugs Irinotecan (Primary) ; HM 30181A
- Indications Solid tumours
- Focus Adverse reactions
- 15 Oct 2014 Results published in a Kinex Pharmaceuticals media release.
- 05 May 2014 According to a Kinex media release, the US FDA has allowed the IND application for Oratecan.
- 05 Dec 2011 Planned End Date changed from 1 Feb 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.